Clal Biotechnology reported ILS5.73M in Cash and Equivalent for its fiscal quarter ending in December of 2023.





Cash And Equivalent Change Date
Arca Biopharma USD 49.52M 2.58M Mar/2026
aTyr Pharma USD 16.16M 6.15M Jun/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
Immunic USD 186.63M 171.15M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
RedHill Biopharma USD 2.87M 1.75M Jun/2025
TherapeuticsMD 523K 89K Jun/2024